Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Arch Virol

Retrieve available abstracts of 86 articles:
HTML format

Single Articles

    November 2022
  1. GRACHEVA AV, Korchevaya ER, Ammour YI, Smirnova DI, et al
    Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light.
    Arch Virol. 2022;167:2181-2191.
    PubMed     Abstract available

  2. DE OLIVEIRA CM, Romano CM, Sussuchi L, Cota BDCV, et al
    SARS-CoV-2 BA.1 and BA.2 coinfection detected by genomic surveillance in Brazil, January 2022.
    Arch Virol. 2022;167:2271-2273.
    PubMed     Abstract available

    October 2022
  3. DABAJA-YOUNIS H, Fuchs E, Shorbaji N, Appel T, et al
    SARS-CoV-2 and seasonal influenza: similarities and disparities.
    Arch Virol. 2022 Oct 21. pii: 10.1007/s00705-022-05615.
    PubMed     Abstract available

  4. KARIMIAN A, Behjati M, Karimian M
    Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2.
    Arch Virol. 2022;167:1931-1946.
    PubMed     Abstract available

  5. YELEMALI P, Hao L, Liu Q
    Mechanisms of host type I interferon response modulation by the nucleocapsid proteins of alpha- and betacoronaviruses.
    Arch Virol. 2022;167:1925-1930.
    PubMed     Abstract available

    August 2022
  6. YANG F, Zhang X, Liu F, Yao H, et al
    Rapid emergence of a PB2 D701N substitution during adaptation of an H9N2 avian influenza virus in mice.
    Arch Virol. 2022 Aug 3. pii: 10.1007/s00705-022-05536.
    PubMed     Abstract available

  7. NAGY A, Stara M, Vodicka R, Cernikova L, et al
    Reverse-zoonotic transmission of SARS-CoV-2 lineage alpha (B.1.1.7) to great apes and exotic felids in a zoo in the Czech Republic.
    Arch Virol. 2022;167:1681-1685.
    PubMed     Abstract available

    July 2022
  8. NGWE TUN MM, Luvai E, Nwe KM, Toume K, et al
    Anti-SARS-CoV-2 activity of various PET-bottled Japanese green teas and tea compounds in vitro.
    Arch Virol. 2022;167:1547-1557.
    PubMed     Abstract available

  9. BAHLAWAN O, Badra R, Semaan H, Fayad N, et al
    Prevalence and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon.
    Arch Virol. 2022;167:1509-1519.
    PubMed     Abstract available

    June 2022
  10. DAHER-NASHIF S, Al-Anany R, Ali M, Erradi K, et al
    COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity.
    Arch Virol. 2022 Jun 20. pii: 10.1007/s00705-022-05495.
    PubMed     Abstract available

    May 2022
  11. TAKIZAWA N, Momose F
    A novel E198K substitution in the PA gene of influenza A virus with reduced susceptibility to baloxavir acid.
    Arch Virol. 2022 May 5. pii: 10.1007/s00705-022-05456.
    PubMed     Abstract available

  12. PIERI M, Nicolai E, Nuccetelli M, Sarubbi S, et al
    Validation of a quantitative lateral flow immunoassay (LFIA)-based point-of-care (POC) rapid test for SARS-CoV-2 neutralizing antibodies.
    Arch Virol. 2022;167:1285-1291.
    PubMed     Abstract available

    April 2022
  13. NAGY A, Cernikova L, Stara M
    A new clade H5N1 highly pathogenic avian influenza genotype detected in Europe in 2021.
    Arch Virol. 2022 Apr 26. pii: 10.1007/s00705-022-05442.
    PubMed     Abstract available

  14. JIANG H, Yang T, Yang C, Lu Y, et al
    Molecular epidemiology and clinical characterization of human rhinoviruses circulating in Shanghai, 2012-2020.
    Arch Virol. 2022;167:1111-1123.
    PubMed     Abstract available

  15. MWANGI P, Mogotsi M, Ogunbayo A, Mooko T, et al
    A decontamination strategy for resolving SARS-CoV-2 amplicon contamination in a next-generation sequencing laboratory.
    Arch Virol. 2022;167:1175-1179.
    PubMed     Abstract available

  16. ALEJO-CANCHO I, Gual-de-Torrella A, Gallego M, Urrutikoetxea-Gutierrez M, et al
    Misidentification of the SARS-CoV-2 Mu variant using commercial mutation screening assays.
    Arch Virol. 2022;167:1141-1144.
    PubMed     Abstract available

  17. ATIYA-NASAGI Y, Milrot E, Makdasi E, Schuster O, et al
    Development of an immunofluorescence assay for detection of SARS-CoV-2.
    Arch Virol. 2022;167:1041-1049.
    PubMed     Abstract available

  18. COLSON P, Delerce J, Burel E, Dahan J, et al
    Emergence in southern France of a new SARS-CoV-2 variant harbouring both N501Y and E484K substitutions in the spike protein.
    Arch Virol. 2022;167:1185-1190.
    PubMed     Abstract available

  19. WANG Y, Li P, Lavrijsen M, Li Y, et al
    Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions.
    Arch Virol. 2022;167:1125-1130.
    PubMed     Abstract available

    March 2022
  20. DA SILVA MS, Mosena ACS, Baumbach L, Demoliner M, et al
    Cattle influenza D virus in Brazil is divergent from established lineages.
    Arch Virol. 2022 Mar 17. pii: 10.1007/s00705-022-05416.
    PubMed     Abstract available

  21. BEHESHTIROUY S, Khani E, Khiali S, Entezari-Maleki T, et al
    Investigational antiviral drugs for the treatment of COVID-19 patients.
    Arch Virol. 2022;167:751-805.
    PubMed     Abstract available

  22. LE TB, Kim HK, Ahn MJ, Zanin M, et al
    Diagnostic performance and clinical feasibility of a novel one-step RT-qPCR assay for simultaneous detection of multiple severe acute respiratory syndrome coronaviruses.
    Arch Virol. 2022;167:871-879.
    PubMed     Abstract available

  23. KLOC M, Uosef A, Wosik J, Kubiak JZ, et al
    Virus interactions with the actin cytoskeleton-what we know and do not know about SARS-CoV-2.
    Arch Virol. 2022;167:737-749.
    PubMed     Abstract available

    February 2022
  24. SALEHI-VAZIRI M, Fazlalipour M, Seyed Khorrami SM, Azadmanesh K, et al
    The ins and outs of SARS-CoV-2 variants of concern (VOCs).
    Arch Virol. 2022;167:327-344.
    PubMed     Abstract available

  25. COLSON P, Fantini J, Yahi N, Delerce J, et al
    Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France.
    Arch Virol. 2022;167:583-589.
    PubMed     Abstract available

  26. WANG HX, Zhang L, Liang ZT, Nie JH, et al
    Infectivity and antigenicity of pseudoviruses with high-frequency mutations of SARS-CoV-2 identified in Portugal.
    Arch Virol. 2022;167:459-470.
    PubMed     Abstract available

  27. KIM Y, Jang G, Lee D, Kim N, et al
    Trypsin enhances SARS-CoV-2 infection by facilitating viral entry.
    Arch Virol. 2022;167:441-458.
    PubMed     Abstract available

  28. ZHANG L, Guo X, Jiang H, Zhao N, et al
    Decreased incidence of acute hemorrhagic conjunctivitis associated with enhanced public health intervention during the COVID-19 epidemic in China, 2020.
    Arch Virol. 2022;167:577-581.
    PubMed     Abstract available

  29. SHRIVASTAVA S, Mhaske ST, Modak MS, Virkar RG, et al
    Emergence of two distinct variants of SARS-CoV-2 and an explosive second wave of COVID-19: the experience of a tertiary care hospital in Pune, India.
    Arch Virol. 2022;167:393-403.
    PubMed     Abstract available

  30. SAFARI I, Elahi E
    Evolution of the SARS-CoV-2 genome and emergence of variants of concern.
    Arch Virol. 2022;167:293-305.
    PubMed     Abstract available

    January 2022
  31. FUMAGALLI MJ, Capato CF, de Castro-Jorge LA, de Souza WM, et al
    Stability of SARS-CoV-2 and other airborne viruses under different stress conditions.
    Arch Virol. 2022;167:183-187.
    PubMed     Abstract available

    December 2021
  32. BUITRAGO SP, Garzon-Ospina D
    Genetic diversity of SARS-CoV-2 in South America: demographic history and structuration signals.
    Arch Virol. 2021;166:3357-3371.
    PubMed     Abstract available

  33. TRIPATHY AS, Vishwakarma S, Trimbake D, Gurav YK, et al
    Pro-inflammatory CXCL-10, TNF-alpha, IL-1beta, and IL-6: biomarkers of SARS-CoV-2 infection.
    Arch Virol. 2021;166:3301-3310.
    PubMed     Abstract available

  34. SHI B, Song Q, Luo X, Song J, et al
    Identification of cryptic putative IRESs within the ORF encoding the nonstructural proteins of the human rhinovirus 16 genome.
    Arch Virol. 2021;166:3373-3386.
    PubMed     Abstract available

    November 2021
  35. VIJAYAKUMAR P, Raut AA, Chingtham S, Murugkar HV, et al
    Proteomic analysis of differential expression of lung proteins in response to highly pathogenic avian influenza virus infection in chickens.
    Arch Virol. 2021 Nov 16. pii: 10.1007/s00705-021-05287.
    PubMed     Abstract available

  36. TSUNEKI-TOKUNAGA A, Kondo T, Kanai K, Itagaki A, et al
    Local spread of influenza A (H1N1) viruses without a mutation for the maximum duration of an epidemic season in Japan.
    Arch Virol. 2021 Nov 11. pii: 10.1007/s00705-021-05301.
    PubMed     Abstract available

  37. WANG S, Liu Y, Yu L, Liang T, et al
    A strain of highly pathogenic porcine reproductive and respiratory syndrome virus: genomic characterization, pathogenicity, and construction of an infectious full-length cDNA clone.
    Arch Virol. 2021;166:3127-3141.
    PubMed     Abstract available

  38. RASTEGAR M, Samadizadeh S, Yasaghi M, Moradi A, et al
    Functional variation (Q63R) in the cannabinoid CB2 receptor may affect the severity of COVID-19: a human study and molecular docking.
    Arch Virol. 2021;166:3117-3126.
    PubMed     Abstract available

  39. DU X, Wu G, Zhu Y, Zhang S, et al
    Exploring the epidemiological changes of common respiratory viruses since the COVID-19 pandemic: a hospital study in Hangzhou, China.
    Arch Virol. 2021;166:3085-3092.
    PubMed     Abstract available

  40. RODRIGUEZ-MALDONADO AP, Vazquez-Perez JA, Cedro-Tanda A, Taboada B, et al
    Emergence and spread of the potential variant of interest (VOI) B.1.1.519 of SARS-CoV-2 predominantly present in Mexico.
    Arch Virol. 2021;166:3173-3177.
    PubMed     Abstract available

    October 2021
  41. JANG Y, Seo SH
    H5 cleavage-site peptide vaccine protects chickens from lethal infection by highly pathogenic H5 avian influenza viruses.
    Arch Virol. 2021 Oct 25. pii: 10.1007/s00705-021-05284.
    PubMed     Abstract available

  42. DOMNICH A, De Pace V, Pennati BM, Caligiuri P, et al
    Evaluation of extraction-free RT-qPCR methods for SARS-CoV-2 diagnostics.
    Arch Virol. 2021;166:2825-2828.
    PubMed     Abstract available

  43. HU J, Stojanovic J, Yasamineh S, Yasamineh P, et al
    The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection.
    Arch Virol. 2021;166:2649-2672.
    PubMed     Abstract available

    September 2021
  44. SUN Y, Mao H, Lou X, Wang X, et al
    Molecular epidemiologic characteristics of hemagglutinin from five waves of avian influenza A (H7N9) virus infection, from 2013 to 2017, in Zhejiang Province, China.
    Arch Virol. 2021 Sep 30. pii: 10.1007/s00705-021-05233.
    PubMed     Abstract available

  45. LAVERACK M, Tallmadge RL, Venugopalan R, Cronk B, et al
    Clinical evaluation of a multiplex real-time RT-PCR assay for detection of SARS-CoV-2 in individual and pooled upper respiratory tract samples.
    Arch Virol. 2021;166:2551-2561.
    PubMed     Abstract available

  46. NAGY A, Basiouni S, Parvin R, Hafez HM, et al
    Evolutionary insights into the furin cleavage sites of SARS-CoV-2 variants from humans and animals.
    Arch Virol. 2021;166:2541-2549.
    PubMed     Abstract available

  47. MARCHIO A, Batejat C, Vanhomwegen J, Feher M, et al
    ddPCR increases detection of SARS-CoV-2 RNA in patients with low viral loads.
    Arch Virol. 2021;166:2529-2540.
    PubMed     Abstract available

  48. ABDELWAHAB SF, Mohamed MK, Ali WY, Ali AS, et al
    Role of polymeric materials in preventing COVID-19 infection.
    Arch Virol. 2021;166:2487-2493.
    PubMed     Abstract available

  49. BOONARKART C, Suptawiwat O, Ruangrung K, Maneechotesuwan K, et al
    Microparticles from human the lower airway show inhibitory activity against respiratory syncytial virus.
    Arch Virol. 2021;166:2579-2584.
    PubMed     Abstract available

  50. MA Y, Jiang H, Wan Z, Li S, et al
    Evolutionary dynamics of group A and B respiratory syncytial virus in China, 2009-2018.
    Arch Virol. 2021;166:2407-2418.
    PubMed     Abstract available

    August 2021
  51. PENG J, Liu ZY, Yu XJ, Chen XY, et al
    Antibody response in COVID-19 patients with and without re-positive RT-PCR results during the convalescent phase.
    Arch Virol. 2021;166:2299-2303.
    PubMed     Abstract available

  52. SHABBIR S, Raza MH, Arshad M, Khan MJ, et al
    The interplay between the immune system and SARS-CoV-2 in COVID-19 patients.
    Arch Virol. 2021;166:2109-2117.
    PubMed     Abstract available

  53. HASHEMI SMA, Thijssen M, Hosseini SY, Tabarraei A, et al
    Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection.
    Arch Virol. 2021;166:2089-2108.
    PubMed     Abstract available

  54. ZHANG L, Hou J, Ma FZ, Li J, et al
    The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis.
    Arch Virol. 2021;166:2071-2087.
    PubMed     Abstract available

    July 2021
  55. ZHOU S, Mao N, Zhang Y, Cui A, et al
    Genetic analysis of human parainfluenza virus type 4 associated with severe acute respiratory infection in children in Luohe City, Henan Province, China, during 2017-2018.
    Arch Virol. 2021 Jul 6. pii: 10.1007/s00705-021-05154.
    PubMed     Abstract available

  56. YUAN HW, Wen HL
    Research progress on coronavirus S proteins and their receptors.
    Arch Virol. 2021;166:1811-1817.
    PubMed     Abstract available

  57. MIRZAEI R, Attar A, Papizadeh S, Jeda AS, et al
    The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19).
    Arch Virol. 2021;166:1819-1840.
    PubMed     Abstract available

    June 2021
  58. ZENG MS, Yu WD, Wang HX, Xu PP, et al
    Puerarin reduces impairment of intestinal and adipose immune responses to influenza virus infection in mice.
    Arch Virol. 2021 Jun 10. pii: 10.1007/s00705-021-05112.
    PubMed     Abstract available

  59. CHEN K, Kong M, Liu J, Jiao J, et al
    Rapid differential detection of subtype H1 and H3 swine influenza viruses using a TaqMan-MGB-based duplex one-step real-time RT-PCR assay.
    Arch Virol. 2021 Jun 6. pii: 10.1007/s00705-021-05127.
    PubMed     Abstract available

  60. ROKIC F, Trgovec-Greif L, Sucic N, Cemeljic N, et al
    Diverse SARS-CoV-2 variants preceded the initial COVID-19 outbreak in Croatia.
    Arch Virol. 2021;166:1735-1739.
    PubMed     Abstract available

  61. PEDREANEZ A, Mosquera-Sulbaran J, Munoz N
    SARS-CoV-2 infection represents a high risk for the elderly: analysis of pathogenesis.
    Arch Virol. 2021;166:1565-1574.
    PubMed     Abstract available

    May 2021
  62. TANG Y, Yang G, Li Y, Wang M, et al
    Protective effects of SP600125 on mice infected with H1N1 influenza A virus.
    Arch Virol. 2021 May 20. pii: 10.1007/s00705-021-05103.
    PubMed     Abstract available

  63. SOKOLOVA AS, Yarovaya OI, Baranova DV, Galochkina AV, et al
    Quaternary ammonium salts based on (-)-borneol as effective inhibitors of influenza virus.
    Arch Virol. 2021 May 13. pii: 10.1007/s00705-021-05102.
    PubMed     Abstract available

  64. SYLVERKEN AA, El-Duah P, Owusu M, Schneider J, et al
    Transmission of SARS-CoV-2 in northern Ghana: insights from whole-genome sequencing.
    Arch Virol. 2021;166:1385-1393.
    PubMed     Abstract available

    April 2021
  65. GONZALEZ-GARCIA LD, Martinez-Castillo M, Vargas-Pavia TA, Ulloa-Aguilar JM, et al
    Inhibition of AMP-activated protein kinase in respiratory syncytial virus infection activates lipid metabolism.
    Arch Virol. 2021;166:1177-1182.
    PubMed     Abstract available

    March 2021
  66. ZINYAKOV NG, Sosipatorova VY, Andriyasov AV, Ovchinnikova EV, et al
    Genetic analysis of genotype G57 H9N2 avian influenza virus isolate A/chicken/Tajikistan/2379/2018 recovered in Central Asia.
    Arch Virol. 2021 Mar 19. pii: 10.1007/s00705-021-05011.
    PubMed     Abstract available

  67. WOUK J, Rechenchoski DZ, Rodrigues BCD, Ribelato EV, et al
    Viral infections and their relationship to neurological disorders.
    Arch Virol. 2021;166:733-753.
    PubMed     Abstract available

  68. DOWLATSHAHI S, Shabani E, Abdekhodaie MJ
    Serological assays and host antibody detection in coronavirus-related disease diagnosis.
    Arch Virol. 2021;166:715-731.
    PubMed     Abstract available

  69. DABBOUS HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, et al
    Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
    Arch Virol. 2021;166:949-954.
    PubMed     Abstract available

  70. VERMA J, Subbarao N
    A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics.
    Arch Virol. 2021;166:697-714.
    PubMed     Abstract available

  71. SARKAR R, Mitra S, Chandra P, Saha P, et al
    Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations.
    Arch Virol. 2021;166:801-812.
    PubMed     Abstract available

  72. HEMMAT N, Asadzadeh Z, Ahangar NK, Alemohammad H, et al
    The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV.
    Arch Virol. 2021;166:675-696.
    PubMed     Abstract available

    February 2021
  73. YANG F, Xiao Y, Liu F, Yao H, et al
    Isolation and characterization of two novel reassortant H5N6 avian influenza viruses from waterfowl in eastern China.
    Arch Virol. 2021 Feb 17. pii: 10.1007/s00705-021-04995.
    PubMed     Abstract available

  74. LI Y, Hu J, Lei J, Fan W, et al
    Development and application of a novel triplex protein microarray method for rapid detection of antibodies against avian influenza virus, Newcastle disease virus, and avian infectious bronchitis virus.
    Arch Virol. 2021 Feb 12. pii: 10.1007/s00705-021-04962.
    PubMed     Abstract available

  75. TSUNEKI-TOKUNAGA A, Kanai K, Itagaki A, Tsuchie H, et al
    Growth capability of epidemic influenza viruses in Japan since the 2009 H1N1 pandemic.
    Arch Virol. 2021 Feb 12. pii: 10.1007/s00705-021-04976.
    PubMed     Abstract available

    January 2021
  76. ALLKOFER A, Garvey M, Ryan E, Lyons R, et al
    Primary vaccination in foals: a comparison of the serological response to equine influenza and equine herpesvirus vaccines administered concurrently or 2 weeks apart.
    Arch Virol. 2021 Jan 7. pii: 10.1007/s00705-020-04846.
    PubMed     Abstract available

  77. SABBAGHI A, Zargar M, Zolfaghari MR, Motamedi-Sedeh F, et al
    Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model.
    Arch Virol. 2021 Jan 6. pii: 10.1007/s00705-020-04900.
    PubMed     Abstract available

  78. NG KT, Takebe Y, Kamarulzaman A, Tee KK, et al
    Genome sequencing and phylogenetic reconstruction reveal a potential fourth rhinovirus species and its worldwide distribution.
    Arch Virol. 2021;166:225-229.
    PubMed     Abstract available

    ceRNA analysis of SARS-CoV-2.
    Arch Virol. 2021;166:271-274.
    PubMed     Abstract available

  80. MOSQUERA-SULBARAN JA, Hernandez-Fonseca H
    Tetracycline and viruses: a possible treatment for COVID-19?
    Arch Virol. 2021;166:1-7.
    PubMed     Abstract available

    December 2020
  81. REHMAN S, Mahmood T, Aziz E, Batool R, et al
    Identification of novel mutations in SARS-COV-2 isolates from Turkey.
    Arch Virol. 2020;165:2937-2944.
    PubMed     Abstract available

    November 2020
  82. YANG X, Liang Y, Bamunuarachchi G, Xu Y, et al
    miR-29a is a negative regulator of influenza virus infection through targeting of the frizzled 5 receptor.
    Arch Virol. 2020 Nov 18. pii: 10.1007/s00705-020-04877.
    PubMed     Abstract available

  83. LIU B, Wang Y, Liu Y, Chen Y, et al
    Molecular evolution and characterization of hemagglutinin and neuraminidase of influenza A(H1N1)pdm09 viruses isolated in Beijing, China, during the 2017-2018 and 2018-2019 influenza seasons.
    Arch Virol. 2020 Nov 3. pii: 10.1007/s00705-020-04869.
    PubMed     Abstract available

  84. DADAR M, Fakhri Y, Bjorklund G, Shahali Y, et al
    The association between the incidence of COVID-19 and the distance from the virus epicenter in Iran.
    Arch Virol. 2020;165:2555-2560.
    PubMed     Abstract available

  85. SHAMIM S, Khan M, Kharaba ZJ, Ijaz M, et al
    Potential strategies for combating COVID-19.
    Arch Virol. 2020;165:2419-2438.
    PubMed     Abstract available

    October 2020
  86. GROHN S, Heinimaki S, Tamminen K, Blazevic V, et al
    Expression of influenza A virus-derived peptides on a rotavirus VP6-based delivery platform.
    Arch Virol. 2020 Oct 16. pii: 10.1007/s00705-020-04847.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.